课题基金 / 基金详情

SAFETY, PHARMACOKINETIC/PHARMACODYNAMIC EFFECT OF PEG HIRUDIN ON ANTICOAGULATION

SAFETY, PHARMACOKINETIC/PHARMACODYNAMIC EFFECT OF PEG HIRUDIN ON ANTICOAGULATION
聚乙二醇水蛭素抗凝的安全性、药代动力学/药效学作用
批准号：
6276372
负责人：
JAMES H CHESEBRO
金额：
$6.67万
依托单位：
MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6276372
关键词：
angina pectoris cardiovascular disorder chemotherapy clinical research dosage drug screening /evaluation heparin hirudins human subject human therapy evaluation myocardial infarction pharmacokinetics

项目摘要

项目成果

JAMES H CHESEBRO的其他基金

相关文献

中文摘要
翻译
本研究的目的是确定最佳剂量的PEG- 水蛭素治疗不稳定型心绞痛或无Q波心肌梗死 并将其疗效与标准药物进行比较 肝素治疗。 决定给予肝素，或给予PEG- 水蛭素，将由电脑随机后，病人给 同意参与。
英文摘要
The objective of this study is to determine the optimal dosage of PEG- Hirudin in patients with unstable angina or non Q-wave myocardial infarction and also to compare its efficacy to that of standard drug therapy with heparin. The decision to give heparin, or to give PEG- Hirudin, will be made randomly by a computer after patient has given consent to participate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLOPIDOGREL DOSING IN HUMAN ARTERIAL THROMBUS FORMATION
CLOPIDOGREL DOSING IN HUMAN ARTERIAL THROMBUS FORMATION
ANTITHROMBOTIC EFFECT OF ESCALATING DOSES OF PEG HIRUDIN IN HUMANS
LIPID LOWERING WITH SIMVASTATINE AFTER ACURE CORONARY SYNDROMES